1131-64-2 Usage
Originator
Declinax,Roche,UK,1967
Uses
Antihypertensive.
Manufacturing Process
27 g of 1,2,3,4-tetrahydroisoquinoline was added at room temperature to a
solution of 28 g of 2-methyl-2-isothiourea sulfate in 80 ml of water. The
resulting mixture was kept at room temperature with occasional shaking. After
a short period of time, methylmercaptan began to escape, and the mixture
warmed up slightly. After then standing for 24 hours, crystals formed. They
were filtered off and rinsed with ice cold water. Recrystallization from
approximately 100 ml of water yielded 1,2,3,4-tetrahydroisoquinoline-2-
carboxamidine sulfate melting at 278°C to 280°C (uncorr.).Another batch prepared in the same manner melted at 284°C to 285°C due to
a minute difference in moisture content.Both batches prepared above analyzed correctly for (C10H13N3)2·H2SO4.
Brand name
Declinax (HoffmannLaRoche).
Therapeutic Function
Antihypertensive
Check Digit Verification of cas no
The CAS Registry Mumber 1131-64-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,1,3 and 1 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1131-64:
(6*1)+(5*1)+(4*3)+(3*1)+(2*6)+(1*4)=42
42 % 10 = 2
So 1131-64-2 is a valid CAS Registry Number.
InChI:InChI=1/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12)
1131-64-2Relevant articles and documents
1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES WITH ANTIHYPERTENSIVE
WENNER
, p. 125 - 126 (1965)
-
The fourth molybdenum containing enzyme mARC: Cloning and involvement in the activation of N-hydroxylated prodrugs
Gruenewald, Sanja,Wahl, Bettina,Bittner, Florian,Hungeling, Helen,Kanzow, Stephanie,Kotthaus, Joscha,Schwering, Ulrike,Mendel, Ralf R.,Clement, Bernd
scheme or table, p. 8173 - 8177 (2009/12/07)
The recently discovered mammalian molybdoprotein mARC1 is capable of reducing N-hydroxylated compounds. Upon reconstitution with cytochrome b 5 and b5 reductase, benzamidoxime, pentamidine, and diminazene amidoximes, N-hydroxymelagatran, guanoxabenz, and N-hydroxydebrisoquine are efficiently reduced. These substances are amidoxime/N-hydroxyguanidine prodrugs, leading to improved bioavailability compared to the active amidines/guanidines. Thus, the recombinant enzyme allows prediction about in vivo reduction of N-hydroxylated prodrugs. Furthermore, the prodrug principle is not dependent on cytochrome P450 enzymes.